Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Transitional Cell 26 Urinary Bladder Neoplasms 23 Ureteral Neoplasms 8 Urologic Neoplasms 4 Urethral Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasms 3 Neoplasm Metastasis 3 Urogenital Neoplasms 2 Peripheral Nervous System Diseases 2 Muscle Invasive Bladder Urothelial Carcinoma 2 Metastatic Urothelial Cancer 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Advanced Bladder Cancer 2 Urothelial Cancer 1 Urologic Diseases 1 Urogenital Diseases 1 Urinary Bladder Diseases 1 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Penile Squamous Cell Carcinoma (PSCC) 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasms by Site 1 Muscle-invasive Bladder Cancer 1

Interventions

pembrolizumab 300 Nivolumab 273 Ipilimumab 250 aldesleukin 137 Cyclophosphamide 136 Interleukin-2 105 trametinib 82 dabrafenib 76 Temozolomide 75 Dacarbazine 74 Vemurafenib 71 fludarabine 68 fludarabine phosphate 62 Biopsy 49 binimetinib 47 sargramostim 44 Radiosurgery 44 Bevacizumab 43 Paclitaxel 42 encorafenib 40 incomplete Freund's adjuvant 39 atezolizumab 38 Radiotherapy 37 Specimen Handling 36 Cisplatin 36 CTLA-4 Antigen 36 Magnetic Resonance Spectroscopy 35 Carboplatin 35 cobimetinib 34 Introns 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × enfortumab vedotin × Clear all

NCT06906822 2025-09-18

PlugIN

Grupo Español Multidisciplinar de Melanoma

Phase 2 Recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡